One of the S&P 500’s big winners for Friday November 21 was AbbVie Inc (ABBV) as the company’s stock climbed 3.33% to $67.36 on volume of 9.17 million shares.
The stock opened at $66.41 and saw an intraday low of $65.75 and an intraday high of $67.36. All told, the day saw a per-share gain of $2.17. The stock’s average daily volume of 13.25 million and 1.59 billion shares outstanding. AbbVie Inc now has a 50-day SMA is $59.51 and 200-day SMA is $54.05, and it has a 52-week high of $67.36 and a 52-week low of $45.5.
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.
Based out of North Chicago, IL, AbbVie Inc has 25000 employees and, after today’s trading, reached a market cap of $107.32 billion. The stock’s P/E Ratio is 28.7. Its P/S ratio is 5.29, P/B ratio is 23.07, and P/FCF ratio is 69.5.
For a full analysis of AbbVie Inc, check out Equities.com’s E.V.A. report for AbbVie Inc.
The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.
While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.
For more news on the financial markets, go to Equities.com. Also, learn more about our Small-Cap Stars. Register to become a member and leverage our proprietary research tools such as the Small-Cap Stars, and robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer